

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/244602 A1

(51) International Patent Classification:

C12N 5/09 (2010.01) *A61K 49/00* (2006.01)
C12Q 1/02 (2006.01) *C12R 1/91* (2006.01)

(21) International Application Number:

PCT/CN2021/098081

(22) International Filing Date:

03 June 2021 (03.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/094778

05 June 2020 (05.06.2020)

CN

(71) Applicant: SHANGHAI LIDE BIOTECH CO., LTD.

[CN/CN]; 3F-302 Building 77-78, 887 Zuchongzhi Road,
Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai
201203 (CN).

(72) Inventor: WEN, Danyi; 3F-302 Building 77-78, 887 Zu-

chongzhi Road, Zhangjiang Hi-Tech Park, Pudong New
Area, Shanghai 201203 (CN).

(74) Agent: SHANGHAI ZHISHENG INTELLECTUAL

PROPERTY OFFICE; Room No. 501, Building No. 51,
1089 North Qin Zhou Road, Shanghai 200233 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: HUMAN NSCLC CELL LINES AND USE THEREOF




图 3

(57) Abstract: Provided are a human non-small cell lung cancer (NSCLC) cell line, a reagent and a kit comprising the present human NSCLC cell lines. Also provided are the use of evaluating the efficacy of anti-NSCLC drugs by using the human NSCLC cell lines and the method for producing the animal model in testing efficacy of drugs or obtaining pharmacological data for said drugs.

[Continued on next page]

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*